(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi (.pdf) dr.ssa Antonella Ferro - Progettoeventi
EGF104900: Updated Overall Survival in ITT 80% 70% 6 Month OS 56% 41% 12 Month OS L N =145 L+T N =146 Died, N (%) 113 (78) 105 (72) Median, months 9.5 14 Hazard ratio (95% CI) 0.74 (0.57, 0.97) Log-rank P value .026 SABCS 2009
Pertuzumab • Pertuzumab, inibitore della dimerizzazione di HER2 • Pertuzumab in combinazione con trastuzumab – un più completo blocco dei signaling pathways di HER – efficacia antitumorale sinergica, come nei modelli preclinici • Questa combinazione ha il potenziale di fornire efficacia al di là di quella di correnti terapie per malattia metastatica HER2-positiva, con incoraggiante tollerabilità
- Page 1 and 2: Utilizzo dei farmaci nei diversi co
- Page 3 and 4: HER2 positive breast cancer “Targ
- Page 5 and 6: Trastuzumab (Herceptin) • Il Tras
- Page 7 and 8: Trastuzumab binds to ErbB2 on tumou
- Page 9 and 10: Antibody-Dependent Cellular Cytotox
- Page 11 and 12: Potenziale meccanismo di trastuzuma
- Page 13: Malattia adiuvante
- Page 17 and 18: DFS: Sequential (Arm B: AC → T
- Page 19 and 20: Malattia Neo- adiuvante
- Page 21 and 22: Studio NOAH: Event Free Survival ne
- Page 23 and 24: Trastuzumab has transformed the pro
- Page 25 and 26: Definition of resistance In most tu
- Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
- Page 29 and 30: Trastuzumab Capecitabine von Minckw
- Page 31 and 32: GBG 26/BIG 03-05: main results Cape
- Page 33 and 34: Phase III, randomised, controlled s
- Page 35 and 36: Lapatinib • Binds to intracellula
- Page 37: Lapatinib may sensitise HER2 positi
- Page 41 and 42: HER2 dimerization is key to signali
- Page 43 and 44: Trastuzumab binds to subdomain IV o
- Page 45 and 46: Trastuzumab and pertuzumab may have
- Page 47 and 48: Receptor-T-DM1 complex is internali
EGF104900: Updated Overall Survival in ITT<br />
80%<br />
70%<br />
6 Month OS<br />
56%<br />
41%<br />
12 Month OS<br />
L<br />
N =145<br />
L+T<br />
N =146<br />
Died, N (%) 113 (78) 105 (72)<br />
Median, months 9.5 14<br />
Hazard ratio (95% CI) 0.74 (0.57, 0.97)<br />
Log-rank P value .026<br />
SABCS 2009
Change language